23 publications in total
Glecirasib plus sitneprotafib in patients with KRAS G12C mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
The Lancet Respiratory Medicine
Dec, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS G12C mutation: two open-label, non-randomised phase 1/2 trials
The Lancet Gastroenterology & Hepatology
Dec, 2025
Preclinical Investigation of Orally Bioavailable, PotentPan-KRAS (ON/OFF) Inhibitor JAB-23E73
AACR-NCI-EORTC
Oct, 2025
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Clinical Cancer Research
May, 2025
Glecirasib in KRAS G12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Nature Medicine
Jan, 2025
Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer
ASCO Gastrointestinal Cancer Symposium
Jan, 2025
Preliminary Results of Patients with Myelofibrosis from a Phase I Trial of JAB-8263, a potent BET Inhibitor
2024 ASH (American Society of Hematology) Annual Meeting
Dec, 2024
Pre-clinical Data of SHP2 Inhibitor JAB-3312 in combo with KRAS G12C Inhibitor Glecirasib
the Fifth RAS Initiative Symposium 2024
Oct, 2024
Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels
2024 ESMO
Sep, 2024
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors
2024 ASCO
Jun, 2024
Updates on Abstract 468214: A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
2024 ASCO
Jun, 2024
JAB-8263, A POTENT BET INHIBITOR, IN MYELOFIBROSIS AND OTHER ADVANCED MYELOID NEOPLASMS: RESULTS FROM A PHASE 1/2A STUDY
2024 EHA
Jun, 2024
Efficacy and Safety of Glecirasib (JAB-21822) Monotherapy in Patients with Advanced NSCLC Harboring KRAS G12C Mutation: Top-Line Results from a Pivotal Phase II Study
2024 ASCO
May, 2024
JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
2024 AACR Annual Meeting
Apr, 2024
JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator
2024 AACR Annual Meeting
Apr, 2024
Preliminary Activity and Safety Results of KRAS G12C Inhibitor Glecirasib (JAB-21822) in Patients with Pancreatic Cancer and Other Solid Tumors
2024 ASCO GI
Jan, 2024
Glecirasib (KRAS G12C Inhibitor) in Combination with JAB-3312 (SHP2 Inhibitor) in Patients with KRAS p.G12C Mutated Solid Tumors
2023 ESMO
Oct, 2023
Glecirasib (JAB-21822, KRAS G12C inhibitor) Monotherapy and in Combination with Cetuximab in Patients with Advanced Colorectal Cancer
2023 JCA-AACR Precision Cancer Medicine International Conference
Jun, 2023
JAB-X1800: a potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73
2023 AACR Annual Meeting
Apr, 2023
JAB-2485: a potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division
2023 AACR Annual Meeting
Apr, 2023

Pages

Platform & Pipeline

Partnership

XML 地图